Noubar Afeyan net worth and biography

Noubar Afeyan Biography and Net Worth

Director of Moderna

Noubar Afeyan (born July 25, 1962), is an American entrepreneur, venture capitalist, inventor, technologist, and CEO. In 2000, Afeyan founded Flagship Pioneering to create and fund early-stage start-ups addressing unmet needs in healthcare and sustainability. He is a Senior Lecturer at the MIT Sloan School of Management. He lectures in the United States and internationally on topics ranging from entrepreneurship, innovation, and venture capital to biological engineering, drug discovery, medical technologies, and renewable energy.

Afeyan is of Armenian heritage and was born in BeirutLebanon. His family moved to MontrealCanada in 1976. Afeyan graduated from McGill University with a BS in Chemical Engineering in 1983. He earned his PhD in Biochemical Engineering from the Massachusetts Institute of Technology in 1987.

In 1988, Afeyan founded PerSeptive Biosystems in Cambridge, MA. While CEO of PerSeptive, Afeyan co-founded and funded numerous other biotechnology companies, including ChemGenics Pharmaceuticals, acquired by Millennium Pharmaceuticals in 1997; Exact Sciences (NASDAQ:EXAS), Agenus (NASDAQ:AGEN); and Color Kinetics, acquired by Philips 2007. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, he became Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics.

In 2000, Afeyan founded Flagship Ventures (renamed Flagship Pioneering in 2016), where he currently serves as Senior Managing Partner and CEO. Flagship Pioneering focuses on creating and investing in first-in-category, high-value life science companies in three principal business sectors: therapeutics, health technologies, and sustainability. The company creates companies through a systemic model of entrepreneurial science. Flagship's team of scientists poses scientific hypotheses, works to finesse them, and conducts proof-of-concept experiments that eventually led to new scientific IP and companies with disruptive potential. Since 2000 this process has led to the launch of around 40 companies. The firm also works with external academic innovations and, in some cases, with early-stage companies looking to partner.

Through his work as an entrepreneur both before and at Flagship Pioneering, Afeyan has founded or helped start numerous companies, including AffinnovaAdnexus (acquired by Bristol Myers Squibb), BG MedicineBIND Therapeutics, Celexion, Eleven Biotherapeutics, Ensemble Therapeutics, Joule Unlimited, LS9, MidoriModerna TherapeuticsPermeon Biologics, Pronutria Biosciences (later renamed Axcella Health) and Seres Therapeutics.

In 2007, Afeyan and David Berry (inventor) co-founded Joule Unlimited, which is developing Solar Fuels—drop-in fuels produced directly from the sun. In March 2010 and in March 2011, Joule was named by Technology Review as one of the 50 Most Innovative Companies. Joule was named as one of the 10 most important emerging technologies in 2010. Joule's unique and innovative approach to fuels led to its being named a Technology Pioneer by the World Economic Forum in 2012 and to its receiving the Silver Medal in the 2011 Wall Street Journal Technology Innovation Awards. Joule's technology has been scaled to a demonstration facility, and the company has announced a commercial partnership with Audi. Afeyan cofounded Moderna Therapeutics with Kenneth Chien of Harvard University and the Karolinka Institutet, Robert Langer of the Massachusetts Institute of Technology, and Derrick Rossi of Boston Children’s Hospital. The company launched from Flagship Pioneering’s innovation foundry, VentureLabs, in 2010. Since launch, Moderna has raised venture funding in excess of $1B.

Since 2000, Afeyan has been teaching courses on entrepreneurship, innovation, and leadership at the Massachusetts Institute of Technology’s Sloan School of Management. From 2007 to 2010, he also served on Boston University’s Board of Overseers. Afeyan has authored numerous scientific publications and patents.

Afeyan is Chairman of the Global Agenda Council on Emerging Technologies of the World Economic Forum. He is also co-founder and board member of the National Competitiveness Foundation of Armenia, a private-public partnership to promote economic development in the former Soviet Republic of Armenia. He serves on the board of Ameriabank, a leading bank in Armenia. Afeyan serves on multiple charitable and corporate boards, including those of Codiak BiosciencesEvelo Biosciences, Joule Unlimited, and Axcella. Since 2008, he has served on the Boston Symphony Orchestra’s Board of Overseers. He is also on the board of the MIT Corporation.

What is Noubar Afeyan's net worth?

The estimated net worth of Noubar Afeyan is at least $294.23 million as of September 21st, 2022. Dr. Afeyan owns 2,407,209 shares of Moderna stock worth more than $294,233,156 as of September 27th. This net worth evaluation does not reflect any other investments that Dr. Afeyan may own. Additionally, Dr. Afeyan receives a salary of $1,120,000.00 as Director at Moderna. Learn More about Noubar Afeyan's net worth.

How old is Noubar Afeyan?

Dr. Afeyan is currently 59 years old. There are 5 older executives and no younger executives at Moderna. The oldest executive at Moderna is Mr. David W. Meline, Chief Financial Officer, who is 65 years old. Learn More on Noubar Afeyan's age.

What is Noubar Afeyan's salary?

As the Director of Moderna, Inc., Dr. Afeyan earns $1,120,000.00 per year. There are 5 executives that earn more than Dr. Afeyan. The highest earning executive at Moderna is Mr. Stephane Bancel, CEO & Director, who commands a salary of $3,160,000.00 per year. Learn More on Noubar Afeyan's salary.

How do I contact Noubar Afeyan?

The corporate mailing address for Dr. Afeyan and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected] Learn More on Noubar Afeyan's contact information.

Has Noubar Afeyan been buying or selling shares of Moderna?

During the last ninety days, Noubar Afeyan has sold $15,531,000.00 in shares of Moderna stock. Most recently, Noubar Afeyan sold 10,000 shares of the business's stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $130.37, for a transaction totalling $1,303,700.00. Following the completion of the sale, the director now directly owns 2,407,209 shares of the company's stock, valued at $313,827,837.33. Learn More on Noubar Afeyan's trading history.

Who are Moderna's active insiders?

Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.

Are insiders buying or selling shares of Moderna?

During the last year, insiders at the sold shares 157 times. They sold a total of 1,716,381 shares worth more than $338,671,396.17. The most recent insider tranaction occured on September, 22nd when CEO Stephane Bancel sold 40,000 shares worth more than $4,990,000.00. Insiders at Moderna own 17.3 % of the company. Learn More about insider trades at Moderna.

Information on this page was last updated on 9/22/2022.

Noubar Afeyan Insider Trading History at Moderna

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2022Sell10,000$130.37$1,303,700.002,407,209View SEC Filing Icon  
9/14/2022Sell10,000$134.00$1,340,000.002,417,209View SEC Filing Icon  
9/7/2022Sell10,000$129.68$1,296,800.002,427,209View SEC Filing Icon  
8/17/2022Sell10,000$165.24$1,652,400.002,447,209View SEC Filing Icon  
8/10/2022Sell10,000$174.09$1,740,900.002,457,209View SEC Filing Icon  
8/3/2022Sell10,000$167.99$1,679,900.002,467,209View SEC Filing Icon  
7/27/2022Sell10,000$161.00$1,610,000.002,477,209View SEC Filing Icon  
7/20/2022Sell10,000$167.00$1,670,000.002,487,209View SEC Filing Icon  
7/13/2022Sell10,000$168.88$1,688,800.002,497,209View SEC Filing Icon  
7/6/2022Sell10,000$154.85$1,548,500.002,507,209View SEC Filing Icon  
6/29/2022Sell10,000$140.47$1,404,700.002,517,209View SEC Filing Icon  
6/22/2022Sell10,000$127.69$1,276,900.002,527,209View SEC Filing Icon  
6/8/2022Sell10,000$147.47$1,474,700.002,537,209View SEC Filing Icon  
6/1/2022Sell10,000$146.31$1,463,100.002,547,209View SEC Filing Icon  
5/25/2022Sell10,000$130.80$1,308,000.002,557,209View SEC Filing Icon  
5/13/2022Sell100,000$134.47$13,447,000.005,816,657View SEC Filing Icon  
5/11/2022Sell10,000$130.74$1,307,400.002,229,673View SEC Filing Icon  
3/31/2021Sell4,888$121.07$591,790.162,101,703View SEC Filing Icon  
3/29/2021Sell1,635,122$124.60$203,736,201.202,101,703View SEC Filing Icon  
2/24/2021Sell1,753,697$146.19$256,372,964.432,101,703View SEC Filing Icon  
2/22/2021Sell1,836,766$164.22$301,633,712.522,101,703View SEC Filing Icon  
See Full Table

Noubar Afeyan Buying and Selling Activity at Moderna

This chart shows Noubar Afeyan's buying and selling at Moderna by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moderna Company Overview

Moderna logo
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $122.23
Low: $120.25
High: $125.16

50 Day Range

MA: $150.91
Low: $119.69
High: $194.18

2 Week Range

Now: $122.23
Low: $115.61
High: $403.30


3,789,335 shs

Average Volume

5,080,633 shs

Market Capitalization

$48.62 billion

P/E Ratio


Dividend Yield